Full Name
MET Proto-Oncogene, Receptor Tyrosine Kinase
Background
This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
Alternative Names
Emibetuzumab; 1365287-97-3; LY2875358; MET; met proto-oncogene (hepatocyte growth factor receptor); hepatocyte growth factor receptor; HGFR; RCCP2; SF receptor; HGF receptor; oncogene MET; HGF/SF receptor; proto-oncogene c-Met; scatter factor receptor
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with MET include Renal Cell Carcinoma, Papillary, 1 and Deafness, Autosomal Recessive 97.
Related Pathways
Its related pathways are Transcriptional misregulation in cancer and RET signaling.
Function
Receptor tyrosine kinases transmit signals from the extracellular matrix to the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes, including proliferation, scattering, morphogenesis, and survival. Ligand binding induces autophosphorylation of MET on the cell surface and provides docking sites for downstream signal molecules. After the ligand is activated, it interacts with the pi3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or adaptor GAB1. The recruitment of these downstream effectors by MET leads to the activation of several signal cascades, including RAS-ERK, PI3 kinase-akt or PLCgamma-PKC. The activation of RAS-ERK is related to morphogenetic effects, while PI3K/AKT is related to pro-survival effects. During embryonic development, MET signals play a role in the development and migration of gastrin, muscle and neural precursors, angiogenesis, and kidney formation. In adults, it is involved in wound healing, organ regeneration and tissue remodeling. Promote the differentiation and proliferation of hematopoietic cells. Adjustable cortical bone formation (through similarity).
Post-translational modifications
Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2. Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis, resulting in decreasing plasma membrane receptor abundance, and in endosomal degradation and/or recycling of internalized receptors.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Emibetuzumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human MET
Indication
Solid tumors, advanced or metastatic
